# Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

> **NCT02610348** · NA · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 122 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
- **BIOLOGICAL:** DTaP-HB-IPV and Pneumococcal polysaccharide vaccines

## Key facts

- **NCT ID:** NCT02610348
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610348, "Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02610348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*